[{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-200","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"TYK","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Tyra Biosciences \/ Alta Partners"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Carlsbad Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Carlsbad Technology","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Carlsbad Technology"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Tyra Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of non-muscle invasive bladder cancer.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including peidatric achondroplasia.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 28, 2024

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including metastatic urothelial cancer.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 24, 2024

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an oral, potent FGFR3-selective tyrosine kinase inhibitor developed from compay's SNAP platform for treatment of hypochondroplasia and achondroplasia.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 07, 2024

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceeds will be used for the development of TYRA-300 an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of achondroplasia.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 02, 2024

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : RA Capital Management

                          Deal Size : $200.0 million

                          Deal Type : Private Placement

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including achondroplasia.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 02, 2024

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-200 is an oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations, it is currently undergoing Phase 1 study for adults with advanced/metastatic intrahepatic cholangiocarcinoma and other advanced soli...

                          Product Name : TYRA-200

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 22, 2023

                          Lead Product(s) : TYRA-200

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias including achondroplasia.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 03, 2023

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an FGFR3 selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract,is developing initially in intrahepatic cholangiocarcinoma.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 29, 2022

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : TYRA-300 is an FGFR3-selective inhibitor designed to be agnostic to the gatekeeper mutation and has demonstrated less hyperphosphatemia mediated by FGFR1 inhibition than pan-FGFR inhibitors in preclinical models.

                          Product Name : TYRA-300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 09, 2022

                          Lead Product(s) : TYRA-300

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank